Actinium Pharmaceuticals (ATNM) Stock Overview
Develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ATNM Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Actinium Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.11 |
| 52 Week High | US$2.41 |
| 52 Week Low | US$1.03 |
| Beta | -0.31 |
| 1 Month Change | -16.54% |
| 3 Month Change | -12.60% |
| 1 Year Change | -3.48% |
| 3 Year Change | -91.93% |
| 5 Year Change | -87.40% |
| Change since IPO | -98.77% |
Recent News & Updates
Shareholder Returns
| ATNM | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -3.5% | -1.2% | -1.4% |
| 1Y | -3.5% | 27.8% | 10.9% |
Return vs Industry: ATNM underperformed the US Biotechs industry which returned 25.7% over the past year.
Return vs Market: ATNM underperformed the US Market which returned 10.7% over the past year.
Price Volatility
| ATNM volatility | |
|---|---|
| ATNM Average Weekly Movement | 8.8% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ATNM has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ATNM's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 25 | Sandesh Seth | www.actiniumpharma.com |
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company advances two clinical stage product candidates, Actimab-A, to treat patients with myeloid malignancies including acute myeloid leukemia and myelodysplastic syndromes; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T for various blood cancer indications and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a preclinical non-prostate specific-membrane antigen targeting radiotherapy utilizing the Actinium-225 radioisotope for patients with prostate cancer.
Actinium Pharmaceuticals, Inc. Fundamentals Summary
| ATNM fundamental statistics | |
|---|---|
| Market cap | US$34.63m |
| Earnings (TTM) | -US$34.60m |
| Revenue (TTM) | US$90.00k |
Is ATNM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ATNM income statement (TTM) | |
|---|---|
| Revenue | US$90.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$90.00k |
| Other Expenses | US$34.69m |
| Earnings | -US$34.60m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.11 |
| Gross Margin | 100.00% |
| Net Profit Margin | -38,443.33% |
| Debt/Equity Ratio | 0% |
How did ATNM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/13 18:23 |
| End of Day Share Price | 2026/02/13 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Actinium Pharmaceuticals, Inc. is covered by 13 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yuan Zhi | B. Riley Securities, Inc. |
| George Zavoico | B. Riley Securities, Inc. |
| John Newman | Canaccord Genuity |